499-81-0

Basic information

• Product Name: 3,5-Pyridinedicarboxylic acid
• Synonyms: PYRIDINE-3,5-DICARBOXYLIC ACID;AKOS 220-60;DINICOTINIC ACID;3,5-PyridinedicarboxylicAcidMin98%;3,5-Pyridinedicarboxylic Acid Min 98%;Pyridine-3,5-dicarboxylicacid,98%;3,5-Pyridinedicarboxylate;5-Carboxynicotinic acid
• CAS NO: 499-81-0
• Molecular Formula: C₇H₅NO₄
• Molecular Weight: 167.12
• EINECS: 207-893-8
• Product Categories: pyridine derivative;Acids and Derivatives;Heterocycles;Pyridine Series;Pyridine;Aromatics;Nicotine Derivatives;Building Blocks;C7;Chemical Synthesis;Heterocyclic Building Blocks;Pyridines
• Mol File: 499-81-0.mol
• Article Data: 12

Chemical Properties

• Melting Point: >300 °C(lit.)
• Boiling Point: 295.67°C (rough estimate)
• Flash Point: 234.2 °C
• Appearance: White to almost white/Powder
• Density: 1.5216 (rough estimate)
• Vapor Pressure: 2.13E-09mmHg at 25°C
• Refractive Index: 1.6280 (estimate)
• Storage Temp.: Refrigerator
• Solubility: 1.0g/l
• PKA: 2.8(at 25℃)
• Water Solubility: insoluble
• BRN: 131640
• CAS DataBase Reference: 3,5-Pyridinedicarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Pyridinedicarboxylic acid(499-81-0)
• EPA Substance Registry System: 3,5-Pyridinedicarboxylic acid(499-81-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-20/21/22
• Safety Statements: 26-36-24/25-36/37/39
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 499-81-0(Hazardous Substances Data)

Usage

Description

3,5-Pyridinedicarboxylic acid, a white crystal powder, is an organic compound with the molecular formula C7H5NO4. It is characterized by the presence of a pyridine ring with two carboxylic acid groups attached at the 3rd and 5th positions. 3,5-Pyridinedicarboxylic acid exhibits competitive inhibition of butyrobetaine hydroxylase, an enzyme involved in the biosynthesis of choline.

Uses

Used in Pharmaceutical Industry:
3,5-Pyridinedicarboxylic acid is used as a pharmaceutical intermediate for the development of various drugs. Its ability to inhibit butyrobetaine hydroxylase makes it a potential candidate in the treatment of conditions related to choline metabolism.
Used in Organic Synthesis:
3,5-Pyridinedicarboxylic acid serves as an important building block in the synthesis of complex organic molecules. Its unique structure allows for further functionalization and modification, making it a versatile compound in the field of organic chemistry.
Used in Enzyme Inhibition Studies:
As a competitive inhibitor of butyrobetaine hydroxylase, 3,5-Pyridinedicarboxylic acid is utilized in research to study the enzyme's function and its role in choline biosynthesis. This can lead to a better understanding of the enzyme's involvement in various biological processes and potential therapeutic applications.

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 4, p. 137, 1967 DOI: 10.1002/jhet.5570040127

InChI:InChI=1/C7H5NO4/c9-6(10)4-1-5(7(11)12)3-8-2-4/h1-3H,(H,9,10)(H,11,12)/p-2

Upstream product

• 591-22-0 3,5-Lutidine 
• 871890-30-1 3,5-diisopropenyl-pyridine 
• 4591-55-3 dimethyl pyridine-3,5-dicarboxylate 
• 110-86-1 pyridine 
• 124-38-9 carbon dioxide 
• 59-67-6 nicotinic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 4591-55-3 dimethyl pyridine-3,5-dicarboxylate 
• 15074-61-0 pyridine-3,5-dicarbonyl dichloride 
• 159236-37-0 N,N'-(pyridine-3,5-diyldicarbonyl)bis[(2S)-2-amino-3-phenylpropanoic acid] 
• 769935-82-2 pyridine-3,5-dicarboxylic acid bis-(3-{4-[tris-(4-tert-butyl-phenyl)-methyl]-phenoxy}-propyl) ester 
• 279239-08-6 N-[(5-Carboxy-3-pyridinyl)carbonyl]-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine 
• 1253421-31-6 pyridine-3,5-dicarboxylic acid [5-[1(R)-[(tert-butoxycarbonyl)oxy]-2-[(tert-butoxycarbonyl)[6-(4-phenylbutoxy)hexyl]amino]ethyl]-2-(di-tert-butoxyphosphoryloxy)benzyl]ester [[11β,16α]-[16,17-((R)-cyclohexylmethylene)bis(oxy)]-11-hydroxypregna-1,4-diene-3,20-dion-21-yl]ester 
• 1313586-44-5 C₅₉H₅₉N₃O₆ 
• 1313744-91-0 1-methyl-3,5-bis(((S)-3-methyl-1-((3,3,3-triphenylpropanoyl)oxy)butan-2-yl)carbamoyl)pyridin-1-ium iodide 
• 1313586-41-2 1-methyl-3,5-bis(((S)-3-methyl-1-((3,3,3-triphenylpropanoyl)oxy)butan-2-yl)carbamoyl)pyridin-1-ium chloride 
• 4663-99-4 pyridine-3,5-dicarboxamide 
• 97031-68-0 3,5-dicarbamoyl-1-(2,6-dichlorobenzyl)pyridinium bromide 
• 78497-33-3 1-benzyl-N,N'-dimethyl-1,4-dihydropyridine-3,5-dicarboxamide 

Relevant articles and documents

Synthesis and crystal structure of metal-organic frameworks [Ln2(pydc-3,5)3(H2O)9]n 3nH2O (Ln = Sm, Eu, Gd, Dy; pydc-3,5 = pyridine-3,5-dicarboxylate) along with the photoluminescent property of its europium one

Rare-earth metal-organic frameworks, [Ln2(pydc)3(H2O)9] n3nH2O (Ln = Sm, Eu, Gd, Dy; pydc = pyridine-3,5-dicarboxylate), were synthesized and characterized by elemental analysis, IR spectra and single-crystal X-ray diffraction. The solid-state photoluminescence measurements exhibited red light-emitting characteristic of europium (III) coordination polymer. The title compounds consist of one-dimensional dual chains, in which each metal atom is nine-coordinated with oxygen atoms.

DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib

This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.